MAY 12, 2016 12:00 PM PDT

Precision Medicine 2.0: Impact Requires Data, Collaboration, Champions

Speaker
  • Chief Medical Officer, DNAnexus
    Biography
      As Chief Medical Officer, David is responsible for driving clinical impact, working closely with management and engineering teams, and with external partners and collaborators. Most recently at Theravance Biopharma, David focused on strategy and business development, and led a product team. Prior, he was a management consultant at the Boston Consulting Group, and was an early member of the Department of Experimental Medicine at Merck Research Labs. He was also a founding advisor of Sage Bionetworks, and a co-founder of the MGH/MIT Center for Assessment Technology and Continuous Health (CATCH). David received his M.D. from the Harvard-MIT Division of Health, Science, and Technology at Harvard Medical School, and his Ph.D. from the Department of Biology at MIT. He trained in internal medicine and endocrinology at the Massachusetts General Hospital, and conducted his post-doctoral research in Doug Melton's lab at the Harvard Stem Cell Institute.

    Abstract

    The extravagant expectations around emerging technologies often gives way to a sense of disillusionment when the lofty expectations are not fulfilled. For genomics and precision precision to escape this cycle, it will be essentially to demonstrate palpable utility, tangible impact. We'll be there when sequencing is embraced not because it’s interesting or edgy, but because it’s so obviously useful that once you’ve seen the benefits you can’t imagine not availing yourself of it.  Achieving impact will require data, collaboration, and champions.

    Learning Objectives:

    • Recognize the cycle in emerging technologies of extravagant expectation followed by disappointment and disillusionment
    • Review examples where precision medicine is impacting patients today

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    Loading Comments...
    Show Resources